Further study is necessary to delineate the role of CDK9-55 and its related pathways in CLL to fully characterize the molecular actions of flavopiridol and to improve CDK9-targeted therapies. The gene discussed is CDK9; the disease is B-cell chronic lymphocytic leukemia.